Business Context and Reporting Period
This Form 8-K, dated February 17, 2021, reports that CF Finance Acquisition Corp. III ("CF III") has entered into a definitive Merger Agreement with AEye, Inc. ("AEye"). Upon closing, CF III will change its name to "AEye Holdings, Inc." and AEye will become a wholly-owned subsidiary. The transaction is structured as a business combination where AEye shareholders will receive CF III Class A common stock based on an exchange ratio derived from a $1.9 billion enterprise value.
Key Financial Metrics and Transaction Terms
- Transaction Value: The "Price Per AEye Share" is calculated based on an aggregate value of $1.9 billion (including the exercise price of assumed options/warrants) divided by the fully-diluted share count.
- Exchange Ratio: As of February 18, 2021, the estimated exchange ratio is 4.6365 shares of CF III Class A common stock for each share of AEye capital stock.
- PIPE Investment: CF III secured $225 million in private investment in public equity (PIPE) through the sale of 22.5 million shares of Class A Common Stock at $10.00 per share. The Sponsor contributed $9.5 million of this total.
- Minimum Cash Requirement: A condition to closing is that CF III must have at least $225 million in "Available Acquiror Cash" and a minimum of $5,000,001 in net tangible assets post-closing.
- Financial Statements: This filing does not contain historical revenue, profit, cash flow, or margin data for AEye. It notes that PCAOB-compliant audited financial statements for AEye are required to be delivered to CF III within four months of the agreement date.
Material Changes and Conditions
The filing details the entry into a material definitive agreement rather than reporting operational changes for a specific period. Key conditions precedent to the transaction include:
- Approval by stockholders of both CF III and AEye.
- Effectiveness of the Form S-4 registration statement.
- Listing approval of the new shares on Nasdaq.
- Consent from holders of certain convertible equity instruments to convert into AEye common stock prior to the merger.
- Waiver of anti-dilution rights by the CF III Sponsor regarding its Class B common stock.
Guidance, Risks, and Unusual Items
Management Commentary and Outlook: The filing includes forward-looking statements regarding AEye's future business plans, product expansion, and revenue growth, but explicitly states these are not guarantees. Management intends to file a proxy statement/prospectus on Form S-4 for stockholder approval.
Risks and Contingencies:
- Termination Rights: Either party may terminate if the transaction is not closed by the earlier of six months after the S-4 filing or 270 days after the agreement date. Termination is also permitted if stockholder approval is not received or if a Material Adverse Effect occurs.
- Redemptions: CF III stockholders have the right to redeem their shares for cash from the trust account, which could impact the net tangible asset requirement.
- Lock-Up Agreements: AEye stockholders are subject to a one-year lock-up period, or until the stock price exceeds $12.00 per share for 20 trading days within a 30-day period (commencing 150 days post-closing).
- COVID-19: The filing notes that risks may be amplified by the economic uncertainty caused by the pandemic.
Investor Verification Checklist
- Verify the final "Price Per AEye Share" and exchange ratio once the fully-diluted share count is finalized in the S-4 filing.
- Confirm the amount of cash remaining in the trust account after any redemptions by CF III public stockholders to ensure the $225 million minimum cash condition is met.
- Review the upcoming Form S-4 proxy statement/prospectus for detailed risk factors and the full text of the Merger Agreement.
- Monitor the status of the PCAOB-compliant audited financial statements for AEye, which are a condition to closing.
- Check for any updates regarding the $250,000 consultant expense liability AEye may face if the agreement is terminated for specific reasons.